Boceprevir and personalized medicine in hepatitis C virus infection

Boceprevir was the first agent, along with telaprevir, of a novel class of direct-acting antivirals that entered clinical practice for the treatment of chronic hepatitis C. Boceprevir is an antiprotease that directly blocks hepatitis C virus (HCV) replication. Two studies in patients with HCV genoty...

Descripción completa

Detalles Bibliográficos
Autores principales: Habersetzer, François, Leboeuf, Céline, Doffoël, Michel, Baumert, Thomas F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513234/
https://www.ncbi.nlm.nih.gov/pubmed/23226068
http://dx.doi.org/10.2147/PGPM.S24259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513234/
https://www.ncbi.nlm.nih.gov/pubmed/23226068
http://dx.doi.org/10.2147/PGPM.S24259

Ejemplares similares